NASDAQ:AFMD

Affimed N.V. Stock Insider Trading

NASDAQ Stock Exchange > Healthcare > Biotechnology

$0.734

+0.0075 (+1.03%)

At Close: Apr 17, 2025

Affimed N.V. Stock Insider Power

Based on the 0 latest insides trades, we have calculated the insider power to be negative at 0. In total, the insiders bought 0 and sold 0 AFMD shares in the last 0 trades.

Historical Insider Trades

There is currently no insider trading information for this ticker.

However, we invite you to learn more about this term and how to use this knowledge to benefit your trading strategy:

Sorry! Image not available at this moment

ABOUT AFFIMED N.V.

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispec...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
F FNA $12.99	0.85%	Apr 15
V VCSH $78.34	0.370%	Apr 15
F FTSM $59.85	0.117%	Apr 15
S SLQD $49.97	0.260%	Apr 15
I ISTB $48.11	0.239%	Apr 15

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by